Does This Provide a Reason to Sell Cytori Therapeutics, Inc. (CYTX)? The Stock Has Formed Bearish Multiple Bottom

January 13, 2018 - By Darrin Black

The stock of Cytori Therapeutics, Inc. (CYTX) shows a multiple bottoms pattern with $0.34 target or 5.00 % below today’s $0.35 share price. The 7 months chart pattern indicates high risk for the $12.43M company. It was reported on Jan, 13 by Finviz.com. If the $0.34 price target is reached, the company will be worth $621,600 less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 7.01% or $0.027 during the last trading session, reaching $0.354. About 1.92M shares traded or 64.42% up from the average. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since January 13, 2017 and is downtrending. It has underperformed by 82.30% the S&P500.

Analysts await Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report earnings on March, 22. They expect $-0.07 earnings per share, up 70.83 % or $0.17 from last year’s $-0.24 per share. After $-0.14 actual earnings per share reported by Cytori Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -50.00 % EPS growth.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Coverage

Among 6 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Cytori Therapeutics has $1000 highest and $0.5 lowest target. $3.35’s average target is 846.33% above currents $0.354 stock price. Cytori Therapeutics had 11 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, September 4 by Zacks. TH Capital maintained it with “Buy” rating and $4.0 target in Monday, August 10 report. The company was maintained on Monday, July 10 by Maxim Group. Maxim Group maintained the stock with “Buy” rating in Friday, August 11 report. The firm has “Neutral” rating by B. Riley & Co given on Tuesday, July 25. The rating was maintained by Maxim Group with “Buy” on Monday, July 24. On Saturday, August 8 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Buy” rating by Maxim Group on Wednesday, May 31.

More recent Cytori Therapeutics, Inc. (NASDAQ:CYTX) news were published by: Seekingalpha.com which released: “Cytori Therapeutics jumps as Maxim sees it as takeover candidate” on January 05, 2018. Also Marketwatch.com published the news titled: “Cytori Therapeutics’ stock plunges toward record low after stock offering …” on April 11, 2017. Seekingalpha.com‘s news article titled: “Cytori Therapeutics’ (CYTX) CEO Marc Hedrick on Q3 2017 Results – Earnings …” with publication date: November 10, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.